171 related articles for article (PubMed ID: 22315496)
1. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype.
Paíno T; Ocio EM; Paiva B; San-Segundo L; Garayoa M; Gutiérrez NC; Sarasquete ME; Pandiella A; Orfao A; San Miguel JF
Haematologica; 2012 Jul; 97(7):1110-4. PubMed ID: 22315496
[TBL] [Abstract][Full Text] [Related]
2. Reply to “Response to “CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype”. Haematologica 2012;97(7):1110-1114.
Paíno T; Paiva B; San Miguel J
Haematologica; 2013 Jan; 98(1):e10. PubMed ID: 23397607
[No Abstract] [Full Text] [Related]
3. Response to "CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype". Haematologica 2012;97(7):1110-4.
Van Hoef ME
Haematologica; 2013 Jan; 98(1):e11. PubMed ID: 23277593
[No Abstract] [Full Text] [Related]
4. Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.
Paíno T; Sarasquete ME; Paiva B; Krzeminski P; San-Segundo L; Corchete LA; Redondo A; Garayoa M; García-Sanz R; Gutiérrez NC; Ocio EM; San-Miguel JF
PLoS One; 2014; 9(3):e92378. PubMed ID: 24658332
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.
Blatt K; Herrmann H; Stefanzl G; Sperr WR; Valent P
Oncotarget; 2016 Oct; 7(40):65627-65642. PubMed ID: 27582537
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.
Kawano Y; Kikukawa Y; Fujiwara S; Wada N; Okuno Y; Mitsuya H; Hata H
Int J Oncol; 2013 Dec; 43(6):1809-16. PubMed ID: 24126540
[TBL] [Abstract][Full Text] [Related]
7. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
8. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Matsui W; Wang Q; Barber JP; Brennan S; Smith BD; Borrello I; McNiece I; Lin L; Ambinder RF; Peacock C; Watkins DN; Huff CA; Jones RJ
Cancer Res; 2008 Jan; 68(1):190-7. PubMed ID: 18172311
[TBL] [Abstract][Full Text] [Related]
9. Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.
Atanackovic D; Panse J; Hildebrandt Y; Jadczak A; Kobold S; Cao Y; Templin J; Meyer S; Reinhard H; Bartels K; Lajmi N; Zander AR; Marx AH; Bokemeyer C; Kröger N
Haematologica; 2011 Oct; 96(10):1512-20. PubMed ID: 21606160
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.
Cho YU; Park CJ; Park SJ; Chi HS; Jang S; Park SH; Seo EJ; Yoon DH; Lee JH; Suh C
J Korean Med Sci; 2013 Apr; 28(4):542-9. PubMed ID: 23580331
[TBL] [Abstract][Full Text] [Related]
11. Nonadherent Spheres With Multiple Myeloma Surface Markers Contain Cells that Contribute to Sphere Formation and Are Capable of Internalizing Extracellular Double-Stranded DNA.
Dolgova EV; Shevela EY; Tyrinova TV; Minkevich AM; Proskurina AS; Potter EA; Orishchenko KE; Zavjalov EL; Bayborodin SI; Nikolin VP; Popova NA; Pronkina NV; Ostanin AA; Chernykh ER; Bogachev SS
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):563-576. PubMed ID: 27431933
[TBL] [Abstract][Full Text] [Related]
12. Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival.
Reghunathan R; Bi C; Liu SC; Loong KT; Chung TH; Huang G; Chng WJ
Oncotarget; 2013 Aug; 4(8):1230-40. PubMed ID: 23985559
[TBL] [Abstract][Full Text] [Related]
13. Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
Lisenko K; Schönland S; Hegenbart U; Wallenwein K; Braun U; Mai EK; Hillengass J; Goldschmidt H; Jauch A; Ho AD; Raab M; Hundemer M
Cytometry B Clin Cytom; 2017 Mar; 92(2):145-152. PubMed ID: 26666746
[TBL] [Abstract][Full Text] [Related]
14. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients.
Hosen N; Matsuoka Y; Kishida S; Nakata J; Mizutani Y; Hasegawa K; Mugitani A; Ichihara H; Aoyama Y; Nishida S; Tsuboi A; Fujiki F; Tatsumi N; Nakajima H; Hino M; Kimura T; Yata K; Abe M; Oka Y; Oji Y; Kumanogoh A; Sugiyama H
Leukemia; 2012 Sep; 26(9):2135-41. PubMed ID: 22430638
[TBL] [Abstract][Full Text] [Related]
15. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
Rawstron AC; Orfao A; Beksac M; Bezdickova L; Brooimans RA; Bumbea H; Dalva K; Fuhler G; Gratama J; Hose D; Kovarova L; Lioznov M; Mateo G; Morilla R; Mylin AK; Omedé P; Pellat-Deceunynck C; Perez Andres M; Petrucci M; Ruggeri M; Rymkiewicz G; Schmitz A; Schreder M; Seynaeve C; Spacek M; de Tute RM; Van Valckenborgh E; Weston-Bell N; Owen RG; San Miguel JF; Sonneveld P; Johnsen HE;
Haematologica; 2008 Mar; 93(3):431-8. PubMed ID: 18268286
[TBL] [Abstract][Full Text] [Related]
16. Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities.
Salama ME; Du S; Efimova O; Heikal NM; Wendlandt E; Toydemir RM; South S; Perkins SL; Hussong JW; Zhan F
Leuk Lymphoma; 2015 Feb; 56(2):426-33. PubMed ID: 24913506
[TBL] [Abstract][Full Text] [Related]
17. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis.
McSweeney PA; Wells DA; Shults KE; Nash RA; Bensinger WI; Buckner CD; Loken MR
Blood; 1996 Jul; 88(2):622-32. PubMed ID: 8695810
[TBL] [Abstract][Full Text] [Related]
19. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.
Bataille R; Jégo G; Robillard N; Barillé-Nion S; Harousseau JL; Moreau P; Amiot M; Pellat-Deceunynck C
Haematologica; 2006 Sep; 91(9):1234-40. PubMed ID: 16956823
[TBL] [Abstract][Full Text] [Related]
20. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice.
Tong AW; Huang YW; Zhang BQ; Netto G; Vitetta ES; Stone MJ
Anticancer Res; 1993; 13(3):593-7. PubMed ID: 8391243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
